832 related articles for article (PubMed ID: 28542874)
1. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
Reich K; Pinter A; Lacour JP; Ferrandiz C; Micali G; French LE; Lomaga M; Dutronc Y; Henneges C; Wilhelm S; Hartz S; Paul C;
Br J Dermatol; 2017 Oct; 177(4):1014-1023. PubMed ID: 28542874
[TBL] [Abstract][Full Text] [Related]
2. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
[No Abstract] [Full Text] [Related]
3. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Paul C; Griffiths CEM; van de Kerkhof PCM; Puig L; Dutronc Y; Henneges C; Dossenbach M; Hollister K; Reich K
J Am Acad Dermatol; 2019 Jan; 80(1):70-79.e3. PubMed ID: 29969700
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
5. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
6. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
7. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
[TBL] [Abstract][Full Text] [Related]
8. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
[TBL] [Abstract][Full Text] [Related]
9. Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A
Puig L; Zhu B; Burge R; Shrom D; Dong Y; Shen W; Mallbris L; Reich K
J Clin Aesthet Dermatol; 2020 Oct; 13(10):18-22. PubMed ID: 33584952
[No Abstract] [Full Text] [Related]
10. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Lebwohl M; Strober B; Menter A; Gordon K; Weglowska J; Puig L; Papp K; Spelman L; Toth D; Kerdel F; Armstrong AW; Stingl G; Kimball AB; Bachelez H; Wu JJ; Crowley J; Langley RG; Blicharski T; Paul C; Lacour JP; Tyring S; Kircik L; Chimenti S; Callis Duffin K; Bagel J; Koo J; Aras G; Li J; Song W; Milmont CE; Shi Y; Erondu N; Klekotka P; Kotzin B; Nirula A
N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
13. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).
Wasel N; Thaçi D; French LE; Conrad C; Dutronc Y; Gallo G; Berggren L; Lacour JP
Dermatol Ther (Heidelb); 2020 Aug; 10(4):663-670. PubMed ID: 32415575
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB; Blauvelt A; Papp KA; Langley RG; Luger T; Ohtsuki M; Reich K; Amato D; Ball SG; Braun DK; Cameron GS; Erickson J; Konrad RJ; Muram TM; Nickoloff BJ; Osuntokun OO; Secrest RJ; Zhao F; Mallbris L; Leonardi CL; ; ;
N Engl J Med; 2016 Jul; 375(4):345-56. PubMed ID: 27299809
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
Leonardi C; Maari C; Philipp S; Goldblum O; Zhang L; Burkhardt N; Ball S; Mallbris L; Gonzalez P; Fernández-Peñas P; Puig L
J Am Acad Dermatol; 2018 Nov; 79(5):824-830.e2. PubMed ID: 29803904
[TBL] [Abstract][Full Text] [Related]
18. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]